Tandingan, Dolores A.
HRN: 25-81-92 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/23/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
09/23/2024
10/03/2024
IV
2.25g
Q6
Diabetic Foot
Waiting Final Action
Indication: Empiric Type of Infection: BloodstreamSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes